Business Wire

ExtraHop ® Expands Presence in EMEA to Meet Enterprise Demand for NDR

4.11.2025 10:00:00 CET | Business Wire | Press Release

Share

ExtraHop®, a leader in modern network detection and response (NDR), today announced its expansion into the Nordics and Benelux markets. This strategic move strengthens the company's European footprint on the heels of a period of significant enterprise growth.

Following a strong 2024, in which ExtraHop more than doubled its sales to Global 2000 customers in EMEA, the company is bringing its proven momentum to two of the continent's most dynamic markets housing global enterprise headquarters and a thriving ecosystem of world-class tech innovators.

To introduce its industry-leading NDR platform to the Nordics and Benelux regions, ExtraHop is extending its distribution agreement with Ignition Technology, a specialist in SaaS-based cybersecurity. Building upon the partnership’s success in the UK and France, the expansion will address growing demand in northern and western Europe, helping customers stay ahead of emerging threats with complete network visibility and context.

“ExtraHop’s continued success across Europe is proof of the undeniable power of our modern NDR platform,” said Andy Philpott, VP, EMEA, ExtraHop. “In the Benelux and Nordics regions, major global enterprises are being targeted by stealthy threats that bypass traditional defenses and move laterally to inflict maximum damage – a challenge that can only be met with the unrivaled visibility ExtraHop offers. With the on-the-ground support and expertise of partners like Ignition Technology, we are well positioned to help security teams in the Benelux and Nordics gain the unparalleled network insights needed to eliminate these sophisticated threats from their network traffic.”

As the attack surface expands and threat actors become more sophisticated, ExtraHop detects and stops advanced, disguised tactics like lateral movement and living off the land attacks. By unifying NDR, network performance management (NPM), intrusion detection (IDS), and forensics in a single, comprehensive platform, ExtraHop provides complete visibility and a powerful defense, backed by industry-leading decryption capabilities and protocol fluency. Recognized as a Leader by Forrester, Gartner, IDC, and GigaOm, ExtraHop delivers the unparalleled insights needed to ensure no threat goes unnoticed.

ExtraHop strengthens Ignition’s cybersecurity ecosystem through integrations with industry leaders such as CrowdStrike. Together, ExtraHop and CrowdStrike give customers unified visibility and control across endpoint, network, and log data within CrowdStrike Falcon® Next-Gen SIEM, helping security teams accelerate detection, investigation, and response while breaking down data silos.

“ExtraHop's industry-leading NDR platform reduces the complexity needed to address network visibility issues across fragmented IT environments, perfectly aligning with our mission to provide innovative and strategic cybersecurity solutions to the enterprise market,” said Peter Ledger, CEO, Ignition Technology. “Their value as a partner is strengthened through existing key integrations with other Ignition partners like CrowdStrike by leveraging both network and endpoint threat intelligence to enhance visibility across enterprise environments. Growing our strategic alliance with ExtraHop ensures our customers can navigate the increasingly complex digital landscape with confidence and agility.”

“At CrowdStrike, we’re building a partner ecosystem that redefines what modern cybersecurity looks like,” said Daniel Bernard, chief business officer, CrowdStrike. “Our collaboration with ExtraHop and Ignition Technology brings together the power of the Falcon platform, ExtraHop’s real-time network intelligence, and Ignition’s regional expertise to give customers unified visibility across every corner of the enterprise. Together, we’re helping organizations transform how they detect, investigate, and respond to threats – delivering the speed, scale, and resilience the modern era demands.”

Additional Resources:

About ExtraHop®

ExtraHop empowers enterprises to stay ahead of evolving threats with the most comprehensive approach to network detection and response (NDR).

Since 2007, the company has helped organizations across the globe extract real-time insights from their hybrid networks with the most in-depth network telemetry. ExtraHop uniquely combines NDR, network performance management (NPM), intrusion detection (IDS), and packet forensics in a single, integrated console for complete network visibility and unparalleled context that supports data-driven security decisions. With a powerful all-in-one sensor and cloud-scale machine learning, the ExtraHop RevealX™ platform enhances SOC productivity, reduces overhead, and elevates security postures.

Unlock the full power of network detection and response with ExtraHop. To learn more, visit www.extrahop.com or follow us on LinkedIn.

© 2025 ExtraHop Networks, Inc., RevealX, RevealX 360, RevealX Enterprise, and ExtraHop are registered trademarks or trademarks of ExtraHop Networks, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104601830/en/

Contacts

ExtraHop Contact
pr@extrahop.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye